Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis

Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR mutants. Results: 16 phase III randomized trials involving 2962 advanced NSCLC EGFR mutants were enrolled. Multiple treatment comp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Zhang, Yaxiong, Sheng, Jin, Yang, Yunpeng, Fang, Wenfeng, Kang, Shiyang, He, Yang, Hong, Shaodong, Zhan, Jianhua, Zhao, Yuanyuan, Xue, Cong, Ma, Yuxiang, Zhou, Ting, Ma, Shuxiang, Gao, Fangfang, Qin, Tao, Hu, Zhihuang, Tian, Ying, Hou, Xue, Huang, Yan, Zhou, Ningning, Zhao, Hongyun, Zhang, Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990517/
https://ncbi.nlm.nih.gov/pubmed/26933807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7713
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia